BIO vs. ILMN: Bio-Rad Laboratories vs. Illumina Stock Comparison
How do Bio-Rad Laboratories (BIO) and Illumina (ILMN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Bio-Rad Laboratories (BIO) and Illumina (ILMN) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | BIO | ILMN |
|---|---|---|
| Name | Bio-Rad Laboratories Inc. | Illumina Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 10.26 billion USD | 32.23 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | February 27, 1980 | July 28, 2000 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIO | ILMN |
|---|---|---|
| Total Return (1Y) | 28.31% | 79.70% |
| Total Return (3Y, Annualized) | 8.52% | 28.16% |
| Total Return (5Y, Annualized) | -11.74% | -10.65% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIO | ILMN |
|---|---|---|
| Volatility (1Y, Annualized) | 36.50% | 48.47% |
| Beta (5Y) | 1.03 | 1.46 |
| Max Drawdown (5Y) | -72.24% | -82.95% |
| Avg. Volume (3M) | 250.78K | 2.77M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIO | ILMN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.66 | 1.56 |
| Sortino Ratio (1Y) | 0.98 | 2.25 |
Profitability
ROE (TTM)
Both Bio-Rad Laboratories (BIO) at 14.27% and Illumina (ILMN) at 32.39% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.39%
- Max
- 109.18%
- ILMN
- 32.39%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Bio-Rad Laboratories (BIO) at 39.45% and Illumina (ILMN) at 19.72% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.72%
- ILMN
- 19.72%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Illumina (ILMN) at 20.02% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.02%
- Max
- 83.12%
- ILMN
- 20.02%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIO | ILMN |
|---|---|---|
| ROE (TTM) | 14.27% | 32.39% |
| ROA (TTM) | 1.50% | 8.32% |
| Net Margin (TTM) | 39.45% | 19.72% |
| Operating Margin (TTM) | 11.82% | 20.02% |
| Gross Margin (TTM) | 52.19% | 67.68% |
Growth
Revenue Growth
Bio-Rad Laboratories (BIO) at 0.65% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Neither Bio-Rad Laboratories (BIO) nor Illumina (ILMN) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | BIO | ILMN |
|---|---|---|
| Revenue Growth (YoY) | 0.65% | -0.66% |
| Revenue Growth (3Y CAGR) | -2.68% | -1.78% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Bio-Rad Laboratories (BIO) at 3.18 and Illumina (ILMN) at 2.63 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ILMN
- 2.63
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Bio-Rad Laboratories (BIO) at 0.18 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.74
- Max
- 1.42
- ILMN
- 0.74
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIO | ILMN |
|---|---|---|
| Current Ratio (MRQ) | 3.18 | 2.63 |
| Debt / Equity (MRQ) | 0.18 | 0.74 |
| Net Debt / EBITDA | -0.73 | 0.85 |
Dividends
Dividend Yield (TTM)
Neither Bio-Rad Laboratories (BIO) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ILMN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Bio-Rad Laboratories (BIO) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ILMN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIO | ILMN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Illumina (ILMN) at 36.68 is closer to its industry’s usual earnings multiple — a discount for BIO, though growth and earnings durability still matter.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.68
- Max
- 85.34
- Q3
- 43.46
- ILMN
- 36.68
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and Illumina (ILMN) at 7.10 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.10
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ILMN
- 7.10
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 1.35 looks cheap against book in the lower P/B ratio quartile, while Illumina (ILMN) at 10.30 carries a premium in the upper quartile — a clear price-to-book gap.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.30
- Max
- 13.53
- ILMN
- 10.30
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIO | ILMN |
|---|---|---|
| P/E Ratio (TTM) | 10.14 | 36.68 |
| P/S Ratio (TTM) | 3.96 | 7.10 |
| P/B Ratio (MRQ) | 1.35 | 10.30 |
| Free Cash Flow Yield (TTM) | 2.65% | 2.67% |